EGFR and breast cancer: It was well tolerated when HER2 vaccine was used in combination with lapatinib (tyrosine kinase inhibitor which interrupts the HER2 and epidermal growth factor receptor (EGFR) pathways) in trastuzumab-refractory breast cancers with HER2-overexpression, and anti-HER2-specific antibodies and HER2-specific T-cells were induced in 100% and 8% of patients respectively.